Vinge advised TransPerfect in connection with the acquisition of Semantix

August 17, 2021 M&A Employment and Benefits

Vinge has advised TransPerfect Global Inc., the world’s leading provider of language and technology solutions for the global market, in connection with the acquisition of Semantix International Group AB, which is the Nordic region’s largest provider of translation and interpreting services.

Semantix has a turnover of approximately MSEK 700 and approximately 320 employees in Sweden, Denmark, Finland, Norway, Spain and Croatia.

Vinge’s team primarily consisted of responsible partner Anders Strid, Anna Jonsson (project manager), Magnus Hedsund, Wilhelm Stenvall, Christian Riddarbo, Emelie Svensäter Jerntorp, Selma Beganovic, Karin Gynnerstadt, Julia Söderdahl, Alexander Lindeberg, Anna Högsten, Gabriella Varga, Jakob Larsson Taghizadeh, Stina Karinsdotter and Erik Ax.


Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024